Literature DB >> 28796410

Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.

Sae Kyung Joo1, Won Kim1, Donghee Kim2, Jung Ho Kim3, Sohee Oh4, Kook Lae Lee1, Mee Soo Chang3, Yong Jin Jung1, Young Ho So5, Myoung Seok Lee5, Jeong Mo Bae3, Byeong Gwan Kim1.   

Abstract

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of heterogeneous metabolic subtypes. This study compared the diagnostic performances of noninvasive fibrosis tests in predicting advanced fibrosis among patients with NAFLD and examined the effects of the subgroups on their diagnostic performances.
METHODS: Three hundred fifteen patients with biopsy-proven NAFLD were prospectively enrolled. Acoustic radiation force impulse imaging (ARFI) was performed to obtain liver stiffness measurements (LSMs). The aspartate aminotransferase-to-alanine aminotransferase ratio (AAR), aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis 4 index (FIB-4), NAFLD fibrosis score (NFS) and BARD score were calculated. The diagnostic performances of noninvasive fibrosis tests were evaluated using the area under the receiver operating characteristic curve (AUROC).
RESULTS: Fibrosis 4 index (FIB-4) showed the highest AUROC for advanced fibrosis (0.866; 95% CI, 0.811-0.922). AUROC subgroup analyses were performed to assess the effects of the subgroups on diagnostic performance. For patients with advanced fibrosis, the APRI, BARD, FIB-4 and NFS AUROCs were significantly different among the radiological steatosis grades. Additionally, the AUROC of ARFI tended to decrease with increasing radiological steatosis severity. FIB-4 and NFS showed significantly lower AUROCs for advanced fibrosis in obese NAFLD than in nonobese NAFLD (P = .002 and P < .001 respectively). However, only radiological steatosis severity was independently associated with advanced fibrosis in multivariable analysis.
CONCLUSIONS: Steatosis severity may affect the diagnostic performances of noninvasive fibrosis tests in patients with NAFLD. The application of different tools should be tailored for various NAFLD subgroups to optimize noninvasive fibrosis assessments.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acoustic radiation force impulse; hepatic fibrosis; hepatic steatosis; liver stiffness

Mesh:

Substances:

Year:  2017        PMID: 28796410     DOI: 10.1111/liv.13549

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

1.  Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups.

Authors:  Aya Sugiyama; Akemi Kurisu; Bunthen E; Serge Ouoba; Ko Ko; Anvarjon Rakhimov; Tomoyuki Akita; Takayuki Harakawa; Toru Sako; Makoto Koshiyama; Takashi Kumada; Junko Tanaka
Journal:  BMC Gastroenterol       Date:  2022-05-13       Impact factor: 2.847

2.  Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.

Authors:  Daniele Pastori; Gregory Y H Lip; Alessio Farcomeni; Francesco Del Sole; Angela Sciacqua; Francesco Perticone; Rossella Marcucci; Elisa Grifoni; Pasquale Pignatelli; Francesco Violi
Journal:  Data Brief       Date:  2018-02-06

3.  Association of fatty liver disease with mortality outcomes in an Eastern Finland male cohort.

Authors:  Olubunmi O Olubamwo; Jyrki K Virtanen; Jussi Pihlajamäki; Tomi-Pekka Tuomainen
Journal:  BMJ Open Gastroenterol       Date:  2019-05-24

4.  Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care.

Authors:  Tracy Davyduke; Puneeta Tandon; Mustafa Al-Karaghouli; Juan G Abraldes; Mang M Ma
Journal:  Hepatol Commun       Date:  2019-07-29

5.  Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results.

Authors:  Annieke C G van Baar; Ulrich Beuers; Kari Wong; Rehan Haidry; Guido Costamagna; Alia Hafedi; Jacques Deviere; Soumitra S Ghosh; Juan Carlos Lopez-Talavera; Leonardo Rodriguez; Manoel P Galvao Neto; Arun Sanyal; Jacques J G H M Bergman
Journal:  JHEP Rep       Date:  2019-11-05

6.  Liver and Nonliver-Related Outcomes at 2 Years Are Not Influenced by the Results of the FIB-4 Test and Liver Elastography in a Real-Life Cohort of Patients with Type 2 Diabetes.

Authors:  Ivica Grgurevic; Nermin Salkic; Sanda Mustapic; Tomislav Bokun; Kristian Podrug; Srecko Marusic; Dario Rahelic; Tomas Matic; Viktoria Skurla; Ivana Mikolasevic
Journal:  Can J Gastroenterol Hepatol       Date:  2021-03-08

7.  Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).

Authors: 
Journal:  Eat Weight Disord       Date:  2021-12-16       Impact factor: 3.008

Review 8.  Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.

Authors:  Yasushi Honda; Masato Yoneda; Kento Imajo; Atsushi Nakajima
Journal:  Int J Mol Sci       Date:  2020-06-05       Impact factor: 5.923

9.  Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Saleh A Alqahtani; Pegah Golabi; James M Paik; Brian Lam; Amir H Moazez; Hazem A Elariny; Zachary Goodman; Zobair M Younossi
Journal:  Obes Surg       Date:  2021-02-22       Impact factor: 4.129

10.  Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.

Authors:  Ferenc Emil Mózes; Jenny A Lee; Emmanuel Anandraj Selvaraj; Arjun Narayan Ajmer Jayaswal; Michael Trauner; Jerome Boursier; Céline Fournier; Katharina Staufer; Rudolf E Stauber; Elisabetta Bugianesi; Ramy Younes; Silvia Gaia; Monica Lupșor-Platon; Salvatore Petta; Toshihide Shima; Takeshi Okanoue; Sanjiv Mahadeva; Wah-Kheong Chan; Peter J Eddowes; Gideon M Hirschfield; Philip Noel Newsome; Vincent Wai-Sun Wong; Victor de Ledinghen; Jiangao Fan; Feng Shen; Jeremy F Cobbold; Yoshio Sumida; Akira Okajima; Jörn M Schattenberg; Christian Labenz; Won Kim; Myoung Seok Lee; Johannes Wiegand; Thomas Karlas; Yusuf Yılmaz; Guruprasad Padur Aithal; Naaventhan Palaniyappan; Christophe Cassinotto; Sandeep Aggarwal; Harshit Garg; Geraldine J Ooi; Atsushi Nakajima; Masato Yoneda; Marianne Ziol; Nathalie Barget; Andreas Geier; Theresa Tuthill; M Julia Brosnan; Quentin Mark Anstee; Stefan Neubauer; Stephen A Harrison; Patrick M Bossuyt; Michael Pavlides
Journal:  Gut       Date:  2021-05-17       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.